FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:331-332 August 4, 1994 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Light, D. W. Related Article by Boren, S. D.

To the Editor: We have some pretty tough days too, for in addition to the clinical, academic, and administrative functions that are part of our careers, we now have to spend many hours persuading health insurance companies that we are not trying to manipulate them into paying more money than Medicare does for kidney transplants, as Dr. Boren insinuates (Feb. 17 issue)¹. He is making his work unnecessarily difficult by equating understandably difficult decisions about whether to approve autologous bone marrow transplantation for patients with metastatic breast cancer with decisions about approval of predialysis transplantation for patients with end-stage . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.